BFG
PTGX icon

Bleakley Financial Group’s Protagonist Therapeutics PTGX Stock Holding History

Bleakley Financial Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Sell
12,538
-264
-2% -$27.6K 0.02% 543
2026
Q1 		$1.35M Buy
+12,802
New +$1.13M 0.02% 462
2025
Q1 		– Sell
-6,367
Closed -$246K – 871
2024
Q4 		$246K Sell
6,367
-664
-9% -$28.9K 0.01% 876
2024
Q3 		$316K Buy
+7,031
New +$284K 0.01% 746
2023
Q4 		– Sell
-10,411
Closed -$174K – 970
2023
Q3 		$174K Buy
+10,411
New +$202K 0.01% 810

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bleakley Financial Group's PTGX Position: Q2 2026 in Review

Bleakley Financial Group reduced its Protagonist Therapeutics (PTGX) stake by 2.1% in Q2 2026, selling an estimated $27.6K and leaving 12,538 shares worth $1.54M. The position accounts for 0.02% of the portfolio, ranked #543.

Bleakley Financial Group first reported a position in PTGX in Q3 2023 and has held it in 5 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bleakley Financial Group held 12,538 shares of Protagonist Therapeutics worth $1.54M as of Q2 2026.
  • Bleakley Financial Group sold 264 Protagonist Therapeutics shares in Q2 2026, an estimated $27.6K.
  • Protagonist Therapeutics made up 0.02% of Bleakley Financial Group's portfolio in Q2 2026, its #543 holding.
  • Bleakley Financial Group first reported a position in Protagonist Therapeutics in Q3 2023 and has held it in 5 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.